GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

55.12 UNCHANGED

Delayed Quote Updated: 4:00 PM EST, Nov 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

GeneDx to Participate in Upcoming Investor Conferences

November 11, 2026

From GeneDx

Via Business Wire

GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients

November 10, 2026

From GeneDx

Via Business Wire

GeneDx (WGS) Q3 2026 Earnings Call Transcript ↗

November 10, 2026

Documentation rules and Medicaid expansion are reshaping volume and margins.

Via The Motley Fool

Topics Earnings

GeneDx Q3 Earnings Call Highlights ↗

November 09, 2026

GeneDx (NASDAQ:WGS) reported third-quarter revenue of $123.1 million and raised its full-year profitability outlook, even as new documentation requirements led the genetic testing company to lower its...

Via MarketBeat

Topics Earnings

GeneDx Holdings (NASDAQ:WGS) Beats Q2 Revenue Estimates and Swings to Adjusted Profit ↗

August 03, 2026

Via Chartmill

GeneDx Reports Third Quarter 2026 Financial Results

November 09, 2026

From GeneDx

Via Business Wire

GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing

November 05, 2026

From GeneDx

Via Business Wire

After-Hours Movers: Oct. 23 Postmarket Gainers and Losers ↗

October 23, 2026

Via Chartmill

GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

October 23, 2026

From GeneDx

Via Business Wire

GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis

October 20, 2026

From GeneDx

Via Business Wire

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

October 19, 2026

From GeneDx

Via Business Wire

GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026

October 07, 2026

From GeneDx

Via Business Wire

GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care

October 02, 2026

From GeneDx

Via Business Wire

GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

September 09, 2026

From GeneDx

Via Business Wire

GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree

September 01, 2026

From GeneDx

Via Business Wire

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

August 24, 2026

From GeneDx

Via Business Wire

GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy

August 11, 2026

From GeneDx

Via Business Wire

GeneDx (WGS) Q2 2026 Earnings Call Transcript ↗

August 10, 2026

Genomic testing volume surged 32% as profitability returned ahead of schedule.

Via The Motley Fool

Topics Earnings

GeneDx to Participate in Upcoming Investor Conferences

August 06, 2026

From GeneDx

Via Business Wire

GeneDx Q2 Earnings Call Highlights ↗

August 03, 2026

GeneDx (NASDAQ:WGS) reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company...

Via MarketBeat

Topics Earnings

GeneDx Reports Second Quarter 2026 Financial Results

August 03, 2026

From GeneDx

Via Business Wire

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

August 03, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with SBS Law

August 03, 2026

From Schall Law

Via GlobeNewswire

GeneDx Holdings Corp. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against GeneDx Holdings Corp. - WGS

July 31, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

GENEDX HOLDINGS DEADLINE MONDAY AUGUST 3rd: Bragar Eagel & Squire, P.C. Urges GeneDx Holdings Corp. Investors to Contact the Firm Regarding Lead Plaintiff Deadline

July 31, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

July 31, 2026

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 31, 2026) - Kahn Swick & Foti, LLC ("KSF")...

Via Newsfile

Topics Fraud Lawsuit

GeneDx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against GeneDx Holdings Corp. - WGS

July 30, 2026

From SkyMedia, LLC

Via GlobeNewswire

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

July 29, 2026

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 29, 2026) - Kahn Swick & Foti, LLC ("KSF")...

Via Newsfile

Topics Fraud Lawsuit

WGS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

July 29, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

July 28, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.